摘要： 胶质母细胞瘤是最常见的成人原发性恶性脑肿瘤。即使经过手术切除和标准同步放化疗及替莫唑胺辅助化疗，患者中位生存期也仅为14.60 个月。近年研究显示，人脂肪源性间充质干细胞（hAT-MSCs）具有向脑胶质瘤趋化迁移的特性，经修饰后携带单纯疱疹病毒胸苷激酶、酵母胞嘧啶脱氨酶-尿嘧啶磷酸核糖基转移酶和兔羧酸酯酶等基因的hAT-MSCs 分别联合更昔洛韦、5-氟胞嘧啶和伊立替康等抗肿瘤前药可发挥有效的抗胶质瘤作用，携带溶瘤病毒和表达肿瘤坏死因子相关凋亡诱导配体的hAT-MSCs 亦可发挥良好的抗肿瘤功效。本文对此领域的研究进展进行总结，以期为基于hAT-MSCs的胶质瘤靶向治疗提供借鉴。

关键词: 间质干细胞移植； 药物载体； 脂肪组织； 肿瘤, 实验性； 神经胶质瘤； 综述

Abstract: Glioblastoma is the most common primary malignant brain tumor in adults. With current standard therapy which includes extensive microsurgical resection along with concurrent chemoradiotherapy and adjuvant temozolomide (TMZ), the median survival of glioblastoma patients is only 14.60 months nowadays. Recent studies demonstrated that human adipose tissue derived mesenchymal stem cells (hAT-MSCs) possessed the glioma-trophic migratory capacity. The engineered hAT-MSCs expressing herpes simplex virus-thymidine kinase (HSV-tk), yeast cytosine deaminase::uracil phosphoribosyltransferase (CDy:: UPRT), and rabbit carboxylesterase (rCE) could exert inhibitory effects on glioma when combined with prodrugs, such as ganciclovir (GCV), 5-fluorocytosine (5-FC) and irinotecan (CPT-11), respectively. hAT-MSCs carrying the oncolytic virus or expressing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) also could inhibit the growth of glioma. This paper summarizes the recent progress in this field to pave the way for hAT-MSCs based targeted therapy of glioma in future.

Key words: Mesenchymal stem cell transplantation, Drug carriers, Adipose tissue, Neoplasms, experimental, Glioma, Review